Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | GGH | Q92820 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374791 | 0.87 | GGH (0.52) | FOLH1GGHUSP2TSHRCYP1A2 | |
| SCHEMBL7612063 | 0.84 | GGH (0.42) | FOLH1GGHGRM8GRM4 | |
| SCHEMBL5052954 | 0.83 | GGH (0.40) | FOLH1GGH | |
| SCHEMBL1373610 | 0.81 | FOLH1 (0.40) | FOLH1GGHGRM8GRM4USP2 | |
| SCHEMBL7607703 | 0.79 | GGH (0.39) | FOLH1GGHGRM3NAALAD2 | |
| SCHEMBL7609509 | 0.79 | ERAP2 (0.40) | FOLH1GRM8GRM4USP2TSHR | |
| SCHEMBL7609517 | 0.79 | GRM8 (0.40) | FOLH1GGHGRM8GRM4 | |
| SCHEMBL2368868 | 0.77 | ALDH1A1 (0.35) | FOLH1GRM8GRM4USP2TSHR | |
| SCHEMBL7605889 | 0.77 | GGH (0.43) | FOLH1GGHTSHRCYP1A2CYP2C19 | |
| SCHEMBL7614354 | 0.76 | CYP2C19 (0.40) | FOLH1GGHTSHRGRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| EP-1161223-A4 | FRAGRANCE AND FLAVOR COMPOSITIONS CONTAINING ODOR NEUTRALIZING AGENTS | SHAW MUDGE & COMPANY (US) | 2002-07-24 | — | — | EP | claimed |
| JP-2002514157-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1161223-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS CONTAINING ODOR NEUTRALIZING AGENTS | Shaw Mudge & Company (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000051560-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS CONTAINING ODOR NEUTRALIZING AGENTS | SHAW MUDGE & COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0957924-A4 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0957924-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-6479471-B1 | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY TO TREAT PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| US-6372726-B1 | ADMINISTERING CARBOXYALKYL PHOSPHONATE, PHOSPHORAMIDATE, OR PHOSPHINE OXIDE DERIVATIVE AS ANTITUMOR AGENT TO TREAT CANCER OF PROSTATE GLAND | GUILFORD PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | disclosed |
| US-6025344-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6011021-A | GLUTAMATE-DERIVED HYDROXYPHOSPHINYL DERIVATIVE. | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | FOLH1 9/4885GGH 54/4885GRM8 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.